The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)
Department of Health and Human Services · Opportunity RFA-CA-27-016
At a glance AI extracted
The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required) (National Institutes of Health) Est. $
Who can apply
- For profit organizations other than small businesses
- Small businesses
- Public and State controlled institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal gov…
- Nonprofits having a 501(c)(3) status with the IRS
Eligible uses
- Health
Typical documents
- Application form (SF-424)
- Project narrative
- Detailed budget
| Award size | Est. $11,800,000 |
|---|---|
| Number of awards | 6 |
| Deadline | 2026-06-30 |
| Posted | 2026-05-08 |
| Eligible applicants | For profit organizations other than small businesses, Small businesses, Public and State controlled institutions of higher education, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Public housing authorities/Indian housing authorities, Special district governm… |
| Activity | Health |
| Funding instrument | Cooperative Agreement |
| CFDA program | Cancer Treatment Research / |
| Org type filter | Nonprofit / For-profit / Higher Ed / State Gov / Local Gov / Tribal Gov / K-12AI-tagged |
| Sector filter | Health / Research / Education / CommunityAI-tagged |
| Use filter | Research / TrainingAI-tagged |
| Source | grants.gov |
| Last updated | 2026-05-14T14:08:51.538023+00:00 |
From the official announcement
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish Lead Academic Organizations (LAOs) as part of the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). ETCTN LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials (e.g., phase 0, phase 1, phase 2, pilot, and other experimental therapeutic clinical trials) involving agents under regulatory sponsorship for New Investigational Drug (IND) applications held by NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). Each ETCTN LAO will participate in clinical trials it leads as well as clinical trials led by other LAOs in the network. Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible institution/organization for the purposes of this application is defined as an academic center/organization in the United States or Canada providing direct medical care to patients that is considered one integral organizational entity under a single financial management system and governance structure. A center/organization (e.g., an academic hospital and/or academic clinic program) for this application is distinguished from large medical centers whose primary mission is patient care. In addition to patient care, academic centers/organizations have comprehensive medical training programs, investigational pharmacies, advanced imaging facilities, and preclinical laboratories that perform basic research.The only Non-domestic (non-U.S.) Entities (Foreign Institutions) allowed in response to this NOFO are Canadian Institutions.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Agency contact
National Institutes of Health
This page summarizes public information from grants.gov via AI extraction. Final eligibility and application terms are set by the issuing agency. AI summaries may contain errors. Verify on the official announcement before applying.